--- title: "Digital Wellness Standards: How WHO, FDA and NICE Are Setting the Bar for Digital Mental Health Technologies" slug: digital-mental-health-technologies-standards-2026 category: health category_label: "Health" author: "BrainWavePost Staff" date: 2026-06-13 tags: ["digital mental health", "DMHT", "WHO", "FDA", "NICE", "hybrid care", "AI"] read_time_minutes: 9 canonical_url: https://brainwavepost.com/article/digital-mental-health-technologies-standards-2026 source: BrainWavePost --- # Digital Wellness Standards: How WHO, FDA and NICE Are Setting the Bar for Digital Mental Health Technologies *Health · 2026-06-13 · BrainWavePost Staff · 9 min read* > Global regulators are converging on a common standard for mental-health apps, AI therapy tools and online support platforms: prove safety, clinical efficacy and privacy — and keep AI augmenting, not replacing, clinical reasoning. > **How this article is sourced** _(info)_ > > All claims below are drawn from primary sources: the World Health Organization's Global Strategy on Digital Health and its 2026 Executive Board report on harmonising digital-health and AI regulation; the U.S. FDA's November 2025 Digital Health Advisory Committee briefing on generative-AI mental-health devices; NICE's Evidence Standards Framework for Digital Health Technologies; the UK MHRA/Wellcome Trust digital mental health technology programme; and peer-reviewed analyses in The Lancet Digital Health and JMIR Mental Health. [1][2][3][4][5][6][7] The conversation around mental-health apps, AI therapy chatbots and online support platforms has moved on from 'do they work?' to 'how do we prove they are safe, effective and private enough to recommend?' This week, that shift was visible across three jurisdictions at once: the World Health Organization advanced a global framework for digital-health and AI governance [2], the U.S. Food and Drug Administration's Digital Health Advisory Committee debated how to regulate generative-AI mental-health devices [3], and the UK's NICE and MHRA continued refining their Evidence Standards Framework and a dedicated digital mental health technology programme. [4][5][6] ![Infographic showing the four evaluation pillars for Digital Mental Health Technologies — safety, clinical efficacy, privacy and hybrid care — with the strapline 'AI augments, not replaces, clinical reasoning'](digital-mental-health-standards-infographic.png) *The four pillars regulators keep returning to for Digital Mental Health Technologies. Sources: NICE Evidence Standards Framework; WHO Global Strategy on Digital Health; FDA DHAC briefing. [2][3][4]* ## What counts as a 'Digital Mental Health Technology'? Across WHO, FDA and NICE documents, Digital Mental Health Technologies (DMHTs) is being used as an umbrella term for software-based products intended to prevent, screen, diagnose, monitor or treat mental-health conditions — including self-guided apps, prescription digital therapeutics, AI-enabled chatbots and online support platforms. [3][4][7] A 2024 Lancet Digital Health analysis argues that DMHTs need a regulatory approach that is robust, proportionate and timely: strict enough to keep patients safe, light enough not to choke off useful innovation. [7] ## Standardising digital care: the global picture WHO's Global Strategy on Digital Health 2020–2027 (updated in 2025) and its 2026 Executive Board report on harmonising data, digital-health and AI regulation push member states to align on common building blocks: governance, interoperability, evaluation evidence, and protection of personal health data. [1][2] For mental health specifically, WHO's Integrated Operational Framework for mental, brain health and substance use and its 2025 mhGAP update make clear that digital tools should be deployed inside — not parallel to — existing care pathways. [8][9] - Safety: tools should comply with recognised safety and quality standards before being offered to patients (NICE Standard 1). [4] - Clinical efficacy: evidence requirements scale with risk — higher-risk DMHTs (for example, those that diagnose or treat) need higher-tier evidence under NICE's framework. [4][5] - Privacy and data protection: WHO's 2026 governance report and the UK MHRA's DMHT programme both flag privacy and lawful data use as non-negotiable for mental-health products. [2][6] - Post-market monitoring: a JMIR Mental Health systematic review on the safety of digital mental-health interventions recommends standardised harm reporting and ongoing surveillance, not just pre-launch trials. [10] ## FDA: what the November 2025 advisory committee actually said On 6 November 2025 the FDA's Digital Health Advisory Committee (DHAC) met to discuss generative-AI-enabled digital mental-health medical devices, using a hypothetical prescription AI chatbot for adults with major depressive disorder as a worked example. [3] The agency's own briefing document and a contemporaneous regulatory analysis describe the committee weighing risk-management expectations, evidence standards, labelling, and post-market monitoring for generative-AI products that interact directly with patients in crisis-prone contexts. [3][11] The FDA already regulates a small number of prescription digital therapeutics in mental health under 21 CFR 882.5801 (computerised behavioural therapy devices) [12], and a 2023 Frontiers in Digital Health perspective traces how its regulatory thinking has had to evolve as the underlying technology — and now generative AI — moves faster than traditional device pathways. [13] > Digital mental-health tools should be held to the same expectations of safety, efficacy and privacy as any other intervention — and AI-enabled tools require additional attention to oversight, transparency and human accountability. > > — Synthesis of WHO Global Strategy on Digital Health, NICE Evidence Standards Framework and FDA DHAC briefing (2025–2026). [2][3][4] ## NICE and the UK: tiered evidence, mental-health specifics NICE's Evidence Standards Framework for Digital Health Technologies classifies DHTs into tiers by function and risk, and sets matching expectations for safety, clinical effectiveness and economic value. [4] A 2024 peer-reviewed analysis from NICE staff in Digital Health (Sage) explains how those expectations are being adapted for the specific risks of digital mental-health tools — including suicide-risk content, vulnerable users and the difficulty of measuring meaningful clinical outcomes. [5] In parallel, the UK government's digital mental health technology collection — a Wellcome Trust-funded MHRA programme — is building dedicated guidance for safe, effective DMHTs in the NHS. [6] ## Hybrid care: AI augments, it does not replace The second theme running through this week's announcements is that none of these regulators are proposing AI as a substitute for clinicians. WHO frames digital tools as part of integrated mental-health services [8][9]; NICE's framework assumes DHTs sit alongside professional care pathways [4][5]; and the FDA's DHAC briefing explicitly considers how AI mental-health devices would interact with prescribers, safety monitoring and escalation to human clinicians. [3] A 2025 Hastings Center Report on AI therapy chatbots reaches the same conclusion: a balanced regulatory approach should harness access benefits while preserving human clinical judgement and accountability. [11] 1. AI can widen access — translating clinical information, supporting between-session work, and reducing administrative burden. [3][11] 2. AI should not make autonomous treatment decisions in mental health without clinician oversight, especially in crisis pathways. [3][11] 3. Evidence of benefit must be matched by evidence of safety, including harm reporting and post-market surveillance. [4][10] 4. Privacy and data protection are part of clinical safety, not a separate compliance checkbox. [2][6] - **2020–2027** — Time horizon of WHO's Global Strategy on Digital Health, updated in 2025 [1] - **Nov 2025** — FDA Digital Health Advisory Committee meeting on generative-AI mental-health devices [3] - **3-tier** — NICE Evidence Standards Framework risk tiers for digital health technologies [4] ## What to watch next Expect three things over the next year. First, more formal FDA guidance following the DHAC discussion, particularly around generative-AI mental-health products and post-market monitoring. [3][11] Second, updated DMHT-specific guidance from the UK MHRA/NICE programme, building on the Wellcome-funded work. [5][6] Third, continued WHO-led harmonisation so that low- and middle-income countries can adopt — and adapt — these standards without rebuilding regulatory infrastructure from scratch. [2] > **If you want to follow this story** _(tip)_ > > Bookmark the WHO digital health hub, the FDA Digital Health Center of Excellence, NICE's Evidence Standards Framework page and the UK government's digital mental health technology collection — these are the primary sources every reputable summary on DMHT standards traces back to. [1][2][4][6] ## The bottom line Digital wellness standards are no longer aspirational. WHO, the FDA and NICE are converging on a shared message: Digital Mental Health Technologies must demonstrate safety, clinical efficacy and privacy before they are recommended at scale, and AI-enabled tools should augment — not replace — the clinical reasoning and human connection at the heart of mental-health care. [2][3][4][11] ## Sources (clickable) - [1] World Health Organization — Global strategy on digital health 2020–2027 (2025 update): https://iris.who.int/server/api/core/bitstreams/a64d584f-015b-471f-9d86-9ea263cfb516/content - [2] WHO Executive Board EB158/19 — 'Harmonization of regulatory approaches, governance and standards for data, digital health and artificial intelligence in the health sector' (2026): https://apps.who.int/gb/ebwha/pdf_files/EB158/B158_19-en.pdf - [3] U.S. FDA — Digital Health Advisory Committee briefing, 'Generative Artificial Intelligence-Enabled Digital Mental Health Medical Devices' (6 Nov 2025): https://www.fda.gov/media/190450/download - [4] NICE — Evidence Standards Framework for Digital Health Technologies (ECD7): https://www.nice.org.uk/corporate/ecd7/chapter/how-to-meet-the-standards - [5] Digital Health (Sage) — 'Considerations for regulation and evaluation of digital mental health technologies' (NICE authors, 2024): https://pmc.ncbi.nlm.nih.gov/articles/PMC11536580/ - [6] UK MHRA / GOV.UK — Digital mental health technology programme (Wellcome Trust-funded, updated 2026): https://www.gov.uk/government/collections/digital-mental-health-technology - [7] The Lancet Digital Health — 'Building robust, proportionate, and timely approaches to regulation and evaluation of digital mental health technologies' (2024): https://pmc.ncbi.nlm.nih.gov/articles/PMC7618730/ - [8] WHO — Integrated operational framework for mental health, brain health and substance use (2024): https://iris.who.int/server/api/core/bitstreams/8a159556-518d-470b-8429-c78a3662af1f/content - [9] WHO — Mental Health Gap Action Programme (mhGAP) guideline executive summary (2025): https://iris.who.int/server/api/core/bitstreams/2b0a3d97-a83a-49e4-862b-5cfc8a373997/content - [10] JMIR Mental Health — 'The Safety of Digital Mental Health Interventions: Systematic Review and Recommendations' (2023): https://mental.jmir.org/2023/1/e47433 - [11] Hastings Center Report — 'Digital Mental Health Tools and AI Therapy Chatbots: A Balanced Approach to Regulation' (2025): https://pmc.ncbi.nlm.nih.gov/articles/PMC12817016/ - [12] U.S. FDA — Regulatory Considerations for Digital Mental Health Therapeutics (FDA presentation, Nov 2025): https://www.fda.gov/media/189835/download - [13] Frontiers in Digital Health — 'FDA regulations and prescription digital therapeutics: Evolving with the technologies they regulate' (2023): https://www.frontiersin.org/journals/digital-health/articles/10.3389/fdgth.2023.1086219/full --- _Canonical article: [https://brainwavepost.com/article/digital-mental-health-technologies-standards-2026](https://brainwavepost.com/article/digital-mental-health-technologies-standards-2026) — © BrainWavePost. Educational content; see the article page for full disclaimers._